Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,121.48
    +7.13 (+0.34%)
     
  • Crude Oil

    83.03
    +1.68 (+2.07%)
     
  • Gold

    2,241.60
    +28.90 (+1.31%)
     
  • Silver

    25.00
    +0.24 (+0.98%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0017 (-0.14%)
     
  • USD/JPY

    151.3840
    +0.1380 (+0.09%)
     
  • Bitcoin USD

    70,898.40
    +2,186.76 (+3.18%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

GSK boss silent on report drugmaker rebuffed Pfizer

LONDON, Nov 3 (Reuters) - GlaxoSmithKline's chief executive declined to comment on Tuesday on a report that Pfizer had approached the British drugmaker about a possible takeover in recent weeks but was rebuffed.

Pfizer has since decided to focus on a transaction with Dublin-based Allergan as a way to clinch a large "inversion" deal that will lower the U.S. company's tax rate through a foreign acquisition.

GSK CEO Andrew Witty told reporters he would not comment on rumours about mergers and acquisitions.

The Financial Times said Pfizer had looked seriously at GSK as a potential target but the U.S. group's overtures received a cool reception from GSK and the talks were now dead, having never reached the point at which a price was discussed.

Suggestions that Pfizer might look to acquire GSK have been rife for more than a year, following Pfizer's unsuccessful attempt to buy smaller British rival AstraZeneca, which collapsed in May 2014.

Buying GSK, which has a market value of 68 billion pounds ($105 billion), would have been another way for Pfizer to shift its tax domicile from the United States, although many analysts believe a deal with Allergan is a simpler proposition for Pfizer CEO Ian Read.

Pfizer's AstraZeneca bid ran into fierce resistance from the Anglo-Swedish company's management, as well as intense political flak in Britain. An attempt to buy GSK, Britain's biggest drugmaker, could have been even more difficult politically.

($1 = 0.6501 pounds) (Reporting by Ben Hirschler; editing by Jason Neely)

Advertisement